BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Special

6 Radiopharmaceutical Programmes and Sites to Watch in APAC

Radioligand therapy is the one modality a region cannot buy its way into late. A vial of lutetium-177 loses half its therapeutic activity in roughly six an...

August 18, 2026 | Analysis

The Sarcopenia Definition Race: The Endpoint Is the Asset

In a category with no approvable indication anywhere in the world, whoever writes the endpoint definition controls who is eligible for a trial, what counts...

August 12, 2026 | Analysis

Reading the Register: What Japan's Provision Plans Actually Say

A register, not an approval list Start with the thing that is most often got wrong, including by people who should know better. The Act on the Safety of ...

August 10, 2026 | Analysis

Why Asia Pacific Must Rethink Chronic Care Before the Demographic Tipping Point

Asia Pacific’s ageing economies are entering a more demanding phase of healthcare planning. As populations live longer, the challenge for healthcare ...

August 10, 2026 | Opinion | By Ambra Debernardi, Head of Employee Benefits and Corporate Relationships, APAC, Zurich Insurance

Aging Is Not an Indication. Asia-Pacific Found Three Ways Around It.

Feature | Longevity and geroscience | BioPharma APAC The closed front door Start with the fact that shapes everything else. There is no jurisdiction on...

August 07, 2026 | Analysis

10 Bioprocessing Bottlenecks and How APAC Plants Are Clearing Them

How this list was built Ten bottlenecks were identified from facility interviews, technical sessions at regional bioprocessing conferences and pub...

August 05, 2026 | Analysis

9 AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped

For most of the past decade, the only honest answer to the question of whether AI drug discovery works in Asia-Pacific was that nobody could yet know. The ...

August 04, 2026 | Analysis

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 04, 2026 | Interaction

Advancing Freeze-to-Store Workflows for the Next Era of Biopharmaceutical Manufacturing

As biologics, biosimilars, and advanced cell and gene therapies continue to reshape the Asia-Pacific biopharmaceutical landscape, manufac...

August 03, 2026 | Expert Insight

7 Manufacturing Technologies Moving From Pilot to Plant in APAC

HOW THE SEVEN WERE CHOSEN Inclusion required evidence of at least two commercial-scale installations in the region, with sites named wherever publ...

August 03, 2026 | Analysis

12 Funding Rounds That Show Where APAC Biotech Capital Is Going

There is a version of this story that lists twelve press releases and calls it analysis. This is not that story. Every round below has already been announc...

July 30, 2026 | News

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028

There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...

July 24, 2026 | Analysis

Stay Connected